BL
REGN icon

BFSG LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

BFSG LLC’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Hold
25
– – ﹤0.01% 533
2026
Q1 		$19.3K Hold
25
– – ﹤0.01% 501
2025
Q4 		$19.3K Hold
25
– – ﹤0.01% 486
2025
Q3 		$14.1K Hold
25
– – ﹤0.01% 512
2025
Q2 		$13.1K Hold
25
– – ﹤0.01% 490
2025
Q1 		$15.9K Hold
25
– – ﹤0.01% 462
2024
Q4 		$17.8K Sell
25
-838
-97% -$703K ﹤0.01% 454
2024
Q3 		$907K Buy
863
+838
+3,352% +$933K 0.11% 163
2024
Q2 		$26.3K Hold
25
– – ﹤0.01% 408
2024
Q1 		$24.1K Hold
25
– – ﹤0.01% 433
2023
Q4 		$22K Buy
+25
New +$20.6K ﹤0.01% 409
2021
Q4 		– Sell
-1,726
Closed -$1.04M – 231
2021
Q3 		$1.04M Buy
+1,726
New +$1.07M 0.16% 133
2020
Q3 		– Sell
-952
Closed -$594K – 196
2020
Q2 		$594K Buy
+952
New +$540K 0.13% 130

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

BFSG LLC's REGN Position: Q2 2026 in Review

BFSG LLC held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 25 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #533.

BFSG LLC first reported a position in REGN in Q2 2020 and has held it in 13 quarters since. The position peaked at $1.04M in Q3 2021. 210 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BFSG LLC held 25 shares of Regeneron Pharmaceuticals worth $15.6K as of Q2 2026.
  • BFSG LLC left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of BFSG LLC's portfolio in Q2 2026, its #533 holding.
  • BFSG LLC first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
  • BFSG LLC's Regeneron Pharmaceuticals position peaked at $1.04M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BFSG LLC's 13F filing for Q2 2026, filed 20 Jul 2026.